Table 4.
Effect of the ASP interruption during COVID-19 pandemic on antibiotic consumption in the 4 units where the program had been active for less than 30 months.
| Antibiotics | Parameter Evaluated | Effect Estimate | LCI | UCI | p Value |
|---|---|---|---|---|---|
| Carbapenems | Change in trend | 1.51 | −1.30 | 4.32 | 0.27 |
| Change in level | 5.30 | −5.63 | 16.2 | 0.32 | |
| Piperacillin/tazobactam | Change in trend | 4.11 | 0.48 | 7.75 | 0.029 |
| Change in level | −3.13 | −13.5 | 7.30 | 0.53 | |
| III/IV Generation cephalosporins | Change in trend | 0.67 | −0.57 | 1.91 | 0.27 |
| Change in level | −2.08 | −8.47 | 4.31 | 0.50 | |
| Aminopenicillins/BLI | Change in trend | 1.65 | −0.15 | 3.46 | 0.07 |
| Change in level | 8.39 | −1.18 | 17.9 | 0.08 | |
| Fluoroquinolones | Change in trend | 1.004 | 0.27 | 1.74 | 0.011 |
| Change in level | −0.95 | −4.61 | 2.71 | 0.59 | |
| Vancomycin | Change in trend | 0.53 | −0.61 | 1.68 | 0.34 |
| Change in level | −1.09 | −6.21 | 4.04 | 0.66 | |
| Linezolid | Change in trend | 0.23 | −0.55 | 1.00 | 0.54 |
| Change in level | 2.14 | −1.87 | 6.16 | 0.27 | |
| Cefazolin | Change in trend | 0.17 | −1.61 | 1.96 | 0.84 |
| Change in level | −3.69 | −13.02 | 5.64 | 0.41 | |
| All antibiotics | Change in trend | 12.9 | 2.12 | 23.7 | 0.022 |
| Change in level | −0.16 | −47.6 | 47.3 | 0.99 | |
| Costs | Change in trend | 358.4 | 50.94 | 665.9 | 0.026 |
| Change in level | 640.3 | −419.7 | 1700.4 | 0.22 |